Global health neglect: How systemic atherosclerosis and medical bias turn 'local' leg disease into a silent pandemic
Original framing: “[Editorial] Peripheral arterial disease: counting what matters” — The Lancet
Marginalized groups bear the brunt of PAD misdiagnosis: Black women in the U.S. are 40% more likely to have PAD attributed to 'arthritis' than white men, while Indigenous Australians report leg pain as 'just part of ageing' due to historical medical abuse (e.g., forced sterilizations tied to vascular neglect). A 2022 *JAMA* study found that Hispanic patients with limited English proficiency wait 18% longer for vascular consultations. The editorial’s silence on these disparities reflects a systemic bias where 'universal' guidelines are designed for the least vulnerable. For example, the *REDUCE-IT* trial’s exclusion of non-white patients led to underdosing of omega-3s in PAD management for years.
The Lancet editorial’s framing of PAD as a 'local' disease is a *trickster* illusion, masking how colonial medicine’s diagnostic thresholds, pharmaceutical profit motives, and cultural biases have conspired to treat atherosclerosis as a regional rather than systemic epidemic.
Indigenous knowledge systems—from Māori *whakapapa* to Inuit *qaggiq* circles—offer proven alternatives to the reactive, procedure-driven model that dominates Western care, yet these are excluded from global guidelines. Historical parallels to 'Bright’s disease' and modern disparities in the *REDUCE-IT* trial reveal a pattern: marginalized groups bear the brunt of misdiagnosis when 'universal' standards are built on privileged cohorts. The solution lies in *decolonizing vascular health* through equity audits, climate-adaptive care, and economic reforms that treat PAD as the public health crisis it is—not a niche condition for specialists, but a symptom of a broken system. The *trick* isn’t just in the diagnosis; it’s in the delay, and the delay is structural.